T78.3XXA Insurance Policy Changes

ICD-10 T78.3XXA is officially defined as "Angioneurotic edema, initial encounter." code T78.3XXA is referenced in 3 tracked payer policy changes from Excellus BlueCross BlueShield and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code T78.3XXA is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Jul 16, 2026Medium impact
Allergy Testing 2.01.10
Percutaneous, combined percutaneous and intracutaneous, intracutaneous, patch, photo patch, photo, inhalation bronchial challenge, ingestion challenge, and gammaglobulin IgE tests are medically appropriate in the diagnosis of the allergic patient, with allergen-specific IgE medically appropriate only under specified circumstances. Allergen-specific IgG when the criteria are not met, the leukocyte histamine release test, ophthalmic and direct nasal mucous membrane tests, peanut allergen-specific ELISA testing, and cytotoxicity, provocative, and Rebuck skin window tests are investigational, and allergy testing for treatment programs such as tolerance induction programs is investigational. The July 16, 2026 update was an annual review with the policy intent unchanged.
Aetna · Identified Oct 2, 2026Medium impact
Hereditary Angioedema (CPB 0782, reviewed 2026-09-10)
Aetna Clinical Policy Bulletin 0782 sets the criteria for hereditary angioedema (HAE) drugs under commercial medical plans, and precertification is required for these agents in applicable plan designs. Cinryze, Dawnzera, Haegarda and Takhzyro are considered medically necessary for prevention of HAE attacks when they are prescribed by or in consultation with a prescriber who specializes in the management of HAE, are not used in combination with another prophylaxis medication, and the member meets the initial criteria, including C1 inhibitor deficiency confirmed by laboratory testing or a normal C1 inhibitor with a qualifying pathogenic variant or a family history of angioedema refractory to high-dose antihistamine therapy for at least one month. Berinert is considered medically necessary for treatment of acute attacks only when the member has a contraindication, intolerance or ineffective response to the equivalent alternative Ruconest, tried for one month, and all other indications of these agents are considered experimental, investigational or unproven.
Aetna · Identified Aug 17, 2026Medium impact
Hair Analysis (CPB 0300, reviewed 2026-04-17)
Aetna considers chemical hair analysis experimental, investigational or unproven, except for diagnosis of suspected chronic arsenic poisoning, and considers hair analysis of brain-derived neurotrophic factor as a predictor of developing psychopathological symptoms in childhood experimental, investigational or unproven. Microscopic evaluation of hair structure (trichogram) may be medically necessary as part of the work-up of members with alopecia or abnormal-appearing or abnormally growing hair.

Watch T78.3XXA

Get one email when a payer policy names T78.3XXA, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code T78.3XXA?

There are 3 tracked policy changes affecting code T78.3XXA, including updates from Excellus BlueCross BlueShield, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code T78.3XXA?

Payers that have issued tracked updates for code T78.3XXA include: Excellus BlueCross BlueShield, Aetna.

How do I get notified when code T78.3XXA policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code T78.3XXA. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code T78.3XXA?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Allergy Testing 2.01.10

Hereditary Angioedema (CPB 0782, reviewed 2026-09-10)

Hair Analysis (CPB 0300, reviewed 2026-04-17)

What insurance policy changes affect code T78.3XXA?

Which payers have updated policy for code T78.3XXA?

How do I get notified when code T78.3XXA policy changes?

Why do payers change policies for code T78.3XXA?